Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro ...
LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on ORKA stock, giving a Buy rating today. Sam Slutsky’s rating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback